Impact of COVID-19 on lung cancer care in New South Wales, Australia: real-world data from the EnRICH Program

被引:0
|
作者
Brown, Bea [1 ]
Young, Jane [2 ]
Galpin, Kirsty [3 ]
Boyer, Michael [4 ]
Chin, Venessa [5 ,6 ]
Brown, Chris [1 ]
Simes, Robert J. [1 ]
机构
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[2] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia
[3] Univ Sydney, Sch Psychol, Psychooncol Cooperat Res Grp PoCoG, Sydney, NSW, Australia
[4] Chris OBrien Lifehouse, Sydney, NSW, Australia
[5] St Vincents Hosp, Sydney, NSW, Australia
[6] Garvan Inst Med Res, Sydney, NSW, Australia
来源
PUBLIC HEALTH RESEARCH & PRACTICE | 2024年 / 34卷 / 03期
关键词
UK;
D O I
10.17061/phrp3432423
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: The coronavirus disease 2019 (COVID-19) pandemic disrupted healthcare systems worldwide, causing substantial changes to routine healthcare delivery. National and international modelling studies have predicted adverse impacts of this disruption. This study aimed to assess the real-world impact of the COVID-19 pandemic on quality of care and outcomes for patients with lung cancer in New South Wales (NSW). Study type: Pre-post observational cohort study using data prospectively collected for the Embedding Research (and Evidence) in Cancer Healthcare (EnRICH) Program. Methods: The study population comprised 2000 patients with lung cancer from six specialist cancer centres in metropolitan and regional NSW. We split this population into two cohorts: the pre-COVID-19 cohort (1143 patients diagnosed from 8 September 2016 to 10 March 2020) and the post-COVID-19 cohort (857 patients diagnosed from 11 March 2020 to 28 October 2021). The main outcome measures were lung cancer clinical quality indicators, 1-year and 2-year overall survival, and patient-reported health-related quality of life and psychological distress. Results: Patient and disease characteristics (e.g. age, gender, cancer stage) were similar for the pre-and post-COVID-19 cohorts, except for histology (non- small cell lung cancer (NSCLC) 88% in the pre-COVID-19 cohort and 84% in the post-COVID-19 cohort; p = 0.008) and region of residence (62% and 55%, respectively, lived in metropolitan areas; p = 0.002). Compared to the pre-COVID-19 cohort, fewer patients in the post-COVID-19 cohort received a diagnosis within 28 days of the first investigation of symptoms (clinical diagnosis: 77% compared with 72%; p = 0.017, pathological diagnosis: 60% compared with 53%; p = 0.005). However, the median time from the first investigation of symptoms to treatment initiation did not differ. One- and 2-year overall survival, quality of life and psychological distress did not differ between cohorts. Conclusions: This analysis found that the COVID-19 pandemic did not significantly adversely affect quality of care and outcomes for patients with lung cancer in NSW. Reassuringly, these results suggest that prioritising urgent health services, such as cancer care and implementing protective mitigation measures were effective in avoiding the predicted adverse outcomes of healthcare service disruption.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
    Sahyoun, Laura C.
    Fetene, Jonathan
    Mcmillan, Chandler
    Protiva, Petr
    Al Bawardy, Badr
    Gaidos, Jill K. J.
    Proctor, Deborah
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (05) : 1654 - 1660
  • [42] Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting
    Corpechot, Christophe
    Verdoux, Marie
    Frank-Soltysiak, Marie
    Grimaldi, Lamiae
    Duclos-Vallee, Jean-Charles
    JOURNAL OF HEPATOLOGY, 2023, 78 : S408 - S409
  • [43] Hospital admissions and place of death prior and during COVID-19: Real-world data from a Brazilian cancer center
    Lucia Nascimento, Karla Lucia
    Philip, Errol James
    Sacchi, Luana
    Pereira, Juliana
    Nazario, Jose
    Matos Neto, Joao Nunes
    Bergerot, Cristiane Decat
    Lee, David
    Bergerot, Paulo Gustavo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [44] Exploring the impact of ursodeoxycholic acid therapy on COVID-19 in a real-world setting
    Grimaldi, L.
    Verdoux, M.
    Frank-Soltysiak, M.
    Cohen, A.
    Duclos-Vallee, J. C.
    Corpechot, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 71 - 72
  • [45] Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
    Laura C. Sahyoun
    Jonathan Fetene
    Chandler McMillan
    Petr Protiva
    Badr Al Bawardy
    Jill K. J. Gaidos
    Deborah Proctor
    Digestive Diseases and Sciences, 2024, 69 : 1654 - 1660
  • [46] The real-world impact of the COVID-19 pandemic on patients with cancer: a multidisciplinary cross-sectional survey
    Bao, Kelvin K. H.
    Cheung, Ka-man
    Chow, James C. H.
    Leung, Carmen W. L.
    Wong, Kam-hung
    HONG KONG MEDICAL JOURNAL, 2023, 29 (02) : 132 - 141
  • [47] COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
    Kherabi, Yousra
    Launay, Odile
    Liem Binh Luong Nguyen
    VIRUSES-BASEL, 2022, 14 (10):
  • [48] Effectiveness of COVID-19 vaccines: findings from real-world studies
    Henry, David A.
    Jones, Mark A.
    Stehlik, Paulina
    Glasziou, Paul P.
    MEDICAL JOURNAL OF AUSTRALIA, 2022, 216 (08) : 431 - 431
  • [49] Symptom study app provides real-world data on COVID-19 vaccines
    Drury, Ruth E.
    O'Connor, Daniel
    LANCET INFECTIOUS DISEASES, 2021, 21 (07): : 890 - 891
  • [50] Hospital outcomes after a COVID-19 diagnosis from January to May 2020 in New South Wales Australia
    Liu, Bette
    Spokes, Paula
    Alfaro-Ramirez, Maria
    Ward, Kate
    Kaldor, John
    COMMUNICABLE DISEASES INTELLIGENCE, 2020, 44